Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sunitinib malate, quantity: 16.706 mg (equivalent: sunitinib, qty 12.5 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - arx-sunitinib is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Bandaríkin - enska - NLM (National Library of Medicine)

dr.reddys laboratories inc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summarybased on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 16.7mg equivalent to sunitinib 12.5mg;   - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to sunitinib 12.5mg   excipient: croscarmellose sodium gelatin ink iron oxide red magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25mg;   - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5mg;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5mg   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 66.8mg equivalent to sunitinib 50mg;   - capsule - 50 mg - active: sunitinib malate 66.8mg equivalent to sunitinib 50mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Bandaríkin - enska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and

Malta - enska - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents

Malta - enska - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents

Malta - enska - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 37.5 mg - antineoplastic agents